Sanofi (NASDAQ:SNY) Receives $62.67 Average PT from Analysts

Key Points

• Sanofi has received an average analyst rating of "Buy", with ten research firms evaluating the stock - one hold, six buy, and three strong buy ratings.
• The average 1-year price target for Sanofi among brokerages is $62.67, indicating potential growth from its current share price of around $47.65.
• Sanofi reported a quarterly earnings per share (EPS) of $0.90, which fell short of analysts' expectations of $0.96, but its revenue of $11.34 billion outperformed estimates.

Shares of Sanofi (NASDAQ:SNY - Get Free Report) have received an average recommendation of "Buy" from the nine analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $62.6667.

Several analysts have issued reports on SNY shares. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Morgan Stanley raised shares of Sanofi from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd.

Sanofi Stock Performance

NASDAQ SNY traded up $0.11 on Friday, hitting $46.97. 3,020,160 shares of the stock were exchanged, compared to its average volume of 2,618,986. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The business's fifty day moving average is $48.54 and its 200 day moving average is $51.00. Sanofi has a 52 week low of $44.73 and a 52 week high of $60.12. The company has a market capitalization of $115.34 billion, a PE ratio of 11.29, a P/E/G ratio of 1.11 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same period last year, the company posted $1.73 earnings per share. The business's revenue was down 7.0% compared to the same quarter last year. Research analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Sanofi by 124.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock valued at $1,344,000 after purchasing an additional 13,358 shares during the period. Axxcess Wealth Management LLC raised its position in shares of Sanofi by 130.5% in the first quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock valued at $568,000 after purchasing an additional 5,794 shares during the period. Ballentine Partners LLC raised its position in shares of Sanofi by 68.7% in the first quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock valued at $1,445,000 after purchasing an additional 10,617 shares during the period. Sowell Financial Services LLC bought a new position in shares of Sanofi in the first quarter valued at about $328,000. Finally, Farther Finance Advisors LLC raised its position in shares of Sanofi by 66.2% in the first quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock valued at $338,000 after purchasing an additional 2,476 shares during the period. 14.04% of the stock is owned by institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.